Please Wait
Applying Filters...
menu
    • menu
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Menu

    Rusfertide

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Protagonist Hosts Investor Event On PV, Rusfertide In New York
    Protagonist Hosts Investor Event On PV, Rusfertide In New York

    29 Jan 2025

    // ACCESSWIRE

    https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/protagonist-to-host-investor-event-with-kol-insights-on-polycythemia-v-975919

    ACCESSWIRE
    29 Jan 2025
    Share Share
    Takeda touts 6 pipeline assets with big sales potential
    Takeda touts 6 pipeline assets with big sales potential

    16 Jan 2025

    // FIERCE PHARMA

    https://www.fiercepharma.com/pharma/jpm25-takeda-spotlights-6-later-stage-assets-could-subvert-entyvio-pressures-20b-collective

    FIERCE PHARMA
    16 Jan 2025
    Share Share
    Protagonist Reports Long Term Rusfertide Results At EHA2024 Congress
    Protagonist Reports Long Term Rusfertide Results At EHA2024 Congress

    14 Jun 2024

    // ACCESSWIRE

    https://www.accesswire.com/viewarticle.aspx?id=877298&lang=en

    ACCESSWIRE
    14 Jun 2024
    Share Share
    Protagonist Presents Rusfertide Phase 2 REVIVE OLE Data At EHA 2024
    Protagonist Presents Rusfertide Phase 2 REVIVE OLE Data At EHA 2024

    14 May 2024

    // ACCESSWIRE

    https://www.accesswire.com/863148/protagonist-therapeutics-announces-oral-presentation-on-long-term-follow-up-of-rusfertide-phase-2-revive-study-open-label-extension-at-the-european-hematology-association-2024-congress

    ACCESSWIRE
    14 May 2024
    Share Share
    Protagonist Announces Closing of Worldwide Rusfertide License
    Protagonist Announces Closing of Worldwide Rusfertide License

    18 Mar 2024

    // ACCESSWIRE

    https://www.accesswire.com/843636/protagonist-therapeutics-announces-closing-of-worldwide-rusfertide-license-and-collaboration-agreement-with-takeda

    ACCESSWIRE
    18 Mar 2024
    Share Share
    New England Journal of Medicine Publishes Results of Positive Ph 2 of Rusfertide
    New England Journal of Medicine Publishes Results of Positive Ph 2 of Rusfertide

    21 Feb 2024

    // ACCESSWIRE

    https://www.accesswire.com/viewarticle.aspx?id=835611&lang=en

    ACCESSWIRE
    21 Feb 2024
    Share Share